Cargando…

Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients

Cumulating reports suggest that acute phase proteins (APPs) have diagnostic and prognostic value in different clinical conditions. Among others, APPs are proposed to serve as markers that help to control the outcome of transplant recipients. Here, we questioned whether plasma concentrations of APPs...

Descripción completa

Detalles Bibliográficos
Autores principales: Janciauskiene, Sabina, Royer, Pierre-Joseph, Fuge, Jan, Wrenger, Sabine, Chorostowska-Wynimko, Joanna, Falk, Christine, Welte, Tobias, Reynaud-Gaubert, Martine, Roux, Antoine, Tissot, Adrien, Magnan, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721309/
https://www.ncbi.nlm.nih.gov/pubmed/33299339
http://dx.doi.org/10.2147/JIR.S272662
_version_ 1783620012751192064
author Janciauskiene, Sabina
Royer, Pierre-Joseph
Fuge, Jan
Wrenger, Sabine
Chorostowska-Wynimko, Joanna
Falk, Christine
Welte, Tobias
Reynaud-Gaubert, Martine
Roux, Antoine
Tissot, Adrien
Magnan, Antoine
author_facet Janciauskiene, Sabina
Royer, Pierre-Joseph
Fuge, Jan
Wrenger, Sabine
Chorostowska-Wynimko, Joanna
Falk, Christine
Welte, Tobias
Reynaud-Gaubert, Martine
Roux, Antoine
Tissot, Adrien
Magnan, Antoine
author_sort Janciauskiene, Sabina
collection PubMed
description Cumulating reports suggest that acute phase proteins (APPs) have diagnostic and prognostic value in different clinical conditions. Among others, APPs are proposed to serve as markers that help to control the outcome of transplant recipients. Here, we questioned whether plasma concentrations of APPs mirror the development of chronic lung allograft dysfunction (CLAD). We performed blinded analysis of serial plasma samples retrospectively collected from 35 lung transplanted patients, of whom 25 developed CLAD and 10 remained stable during the follow-up period of 3 to 4.5 years. Albumin (ALB), alpha1-antitrypsin (AAT), high sensitivity C-reactive protein (CRPH), antithrombin-3 (AT3), ceruloplasmin (CER), and alpha2-macroglobulin (A2MG) were measured by the nephelometric method. We found that within the first six months post-transplantation, levels of A2MG, CER and AAT were higher in stable patients relative to those who later developed CLAD. Moreover, in stable patient’s plasma CRPH levels decreased during the follow-up period whereas opposite, in those developing CLAD, the CRPH gradually increased. The ALB levels became significantly lower at the end of the follow-up period in CLAD relative to a stable group. A logistic regression model based on A2MG, CER and AT3 at cut-offs levels of ≥175.5 mg/dL, ≥37.8 mg/dL and ≥27.35 mg/dL enabled to discriminate between stable and CLAD patients with a sensitivity of 87.5%, 100% and 62.5%, and specificity of 65.9%, 72.7% and 79.5%, respectively. We identified A2MG (below 175.5 mg/dL) as an independent predictor of CLAD (hazard ratio 11.5, 95% CI (1.5–91.3), p<0.021). Our findings suggest that profiles of certain APPs may help to predict the development of lung dysfunction at the very early stages after transplantation.
format Online
Article
Text
id pubmed-7721309
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77213092020-12-08 Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients Janciauskiene, Sabina Royer, Pierre-Joseph Fuge, Jan Wrenger, Sabine Chorostowska-Wynimko, Joanna Falk, Christine Welte, Tobias Reynaud-Gaubert, Martine Roux, Antoine Tissot, Adrien Magnan, Antoine J Inflamm Res Clinical Trial Report Cumulating reports suggest that acute phase proteins (APPs) have diagnostic and prognostic value in different clinical conditions. Among others, APPs are proposed to serve as markers that help to control the outcome of transplant recipients. Here, we questioned whether plasma concentrations of APPs mirror the development of chronic lung allograft dysfunction (CLAD). We performed blinded analysis of serial plasma samples retrospectively collected from 35 lung transplanted patients, of whom 25 developed CLAD and 10 remained stable during the follow-up period of 3 to 4.5 years. Albumin (ALB), alpha1-antitrypsin (AAT), high sensitivity C-reactive protein (CRPH), antithrombin-3 (AT3), ceruloplasmin (CER), and alpha2-macroglobulin (A2MG) were measured by the nephelometric method. We found that within the first six months post-transplantation, levels of A2MG, CER and AAT were higher in stable patients relative to those who later developed CLAD. Moreover, in stable patient’s plasma CRPH levels decreased during the follow-up period whereas opposite, in those developing CLAD, the CRPH gradually increased. The ALB levels became significantly lower at the end of the follow-up period in CLAD relative to a stable group. A logistic regression model based on A2MG, CER and AT3 at cut-offs levels of ≥175.5 mg/dL, ≥37.8 mg/dL and ≥27.35 mg/dL enabled to discriminate between stable and CLAD patients with a sensitivity of 87.5%, 100% and 62.5%, and specificity of 65.9%, 72.7% and 79.5%, respectively. We identified A2MG (below 175.5 mg/dL) as an independent predictor of CLAD (hazard ratio 11.5, 95% CI (1.5–91.3), p<0.021). Our findings suggest that profiles of certain APPs may help to predict the development of lung dysfunction at the very early stages after transplantation. Dove 2020-11-30 /pmc/articles/PMC7721309/ /pubmed/33299339 http://dx.doi.org/10.2147/JIR.S272662 Text en © 2020 Janciauskiene et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Janciauskiene, Sabina
Royer, Pierre-Joseph
Fuge, Jan
Wrenger, Sabine
Chorostowska-Wynimko, Joanna
Falk, Christine
Welte, Tobias
Reynaud-Gaubert, Martine
Roux, Antoine
Tissot, Adrien
Magnan, Antoine
Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
title Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
title_full Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
title_fullStr Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
title_full_unstemmed Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
title_short Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
title_sort plasma acute phase proteins as predictors of chronic lung allograft dysfunction in lung transplant recipients
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721309/
https://www.ncbi.nlm.nih.gov/pubmed/33299339
http://dx.doi.org/10.2147/JIR.S272662
work_keys_str_mv AT janciauskienesabina plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT royerpierrejoseph plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT fugejan plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT wrengersabine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT chorostowskawynimkojoanna plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT falkchristine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT weltetobias plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT reynaudgaubertmartine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT rouxantoine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT tissotadrien plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients
AT magnanantoine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients